Related Experiment Video
Updated: Jan 13, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Chronic Urticaria Part II: Clinical management and therapeutics
Peyton V Warp1, Ana Maria Giménez-Arnau2, Brian S Kim3
1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract:
Chronic urticaria (CU) is a mast-cell driven disease characterized by recurrent wheals, angioedema, or both, lasting more than six weeks. Timely, appropriate treatment is essential to achieve complete disease control, minimize burden, and improve quality of life. The goal of management is elimination of symptoms with safe, effective therapies at the lowest necessary dose. This two-part continuing medical education series provides a comprehensive review of CU. Part II focuses on the complex management of CU including the role of antihistamines, immunosuppressants, and biologics, as well as novel approaches. The CU therapeutic landscape is evolving, with investigations ongoing for biologics, small molecules, and specific mast cell-directed agents.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Myocarditis III: Medical Management
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Nephrotic Syndrome III : Nursing Management
Atherosclerosis III: Management

